ATE340570T1 - 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon - Google Patents

3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon

Info

Publication number
ATE340570T1
ATE340570T1 AT03767529T AT03767529T ATE340570T1 AT E340570 T1 ATE340570 T1 AT E340570T1 AT 03767529 T AT03767529 T AT 03767529T AT 03767529 T AT03767529 T AT 03767529T AT E340570 T1 ATE340570 T1 AT E340570T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulations
triiodothyronine
thyromimetic
triiodothyronine sulfate
sulfate
Prior art date
Application number
AT03767529T
Other languages
English (en)
Inventor
Aldo Pinchera
Ferruccio Santini
Original Assignee
Bracco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Spa filed Critical Bracco Spa
Application granted granted Critical
Publication of ATE340570T1 publication Critical patent/ATE340570T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Plasma & Fusion (AREA)
  • Electrochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03767529T 2002-11-13 2003-11-11 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon ATE340570T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI20022394 ITMI20022394A1 (it) 2002-11-13 2002-11-13 Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.

Publications (1)

Publication Number Publication Date
ATE340570T1 true ATE340570T1 (de) 2006-10-15

Family

ID=32310157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03767529T ATE340570T1 (de) 2002-11-13 2003-11-11 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon

Country Status (13)

Country Link
US (5) US9012438B2 (de)
EP (2) EP1560575B1 (de)
JP (2) JP5301074B2 (de)
CN (2) CN101406467A (de)
AT (1) ATE340570T1 (de)
AU (1) AU2003292006A1 (de)
CY (1) CY1107312T1 (de)
DE (1) DE60308718T2 (de)
DK (1) DK1560575T3 (de)
ES (1) ES2273045T3 (de)
IT (1) ITMI20022394A1 (de)
PT (1) PT1560575E (de)
WO (1) WO2004043452A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110713A1 (it) * 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
MX348467B (es) * 2011-04-08 2017-06-13 Bracco Imaging Spa Proceso para la preparación de un derivado sulfatado de 3,5-diiodo-o-[3-iodofenil]-l-tirosina.
CN102507919A (zh) * 2011-11-08 2012-06-20 江苏省原子医学研究所 一种标记3,3’-二碘甲腺氨酸硫酸化物的方法及检测试剂盒
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
KR20170023061A (ko) 2014-06-18 2017-03-02 테티스 파마수티컬스 엘엘씨 활성제의 미네랄 아미노산 복합체
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
JP6968603B2 (ja) * 2017-07-10 2021-11-17 キヤノン株式会社 画像形成装置、画像形成方法、プログラム
JP2021531478A (ja) * 2018-07-13 2021-11-18 エーギルバイオ エービー 甲状腺機能障害の診断のためのバイオセンサー
WO2024129551A1 (en) * 2022-12-16 2024-06-20 Merck Sharp & Dohme Llc Solid dosage form of a small molecule antiviral and uses thereof
WO2025245024A1 (en) * 2024-05-20 2025-11-27 Regents Of The University Of Minnesota Compositions comprising liothyronine and methods of making thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993928A (en) 1957-01-15 1961-07-25 Glaxo Lab Ltd Preparation of triiodothyronine
US2970165A (en) 1957-10-01 1961-01-31 Warner Lambert Pharmaceutical Sulfate compounds
US3313839A (en) 1963-07-01 1967-04-11 Gen Aniline & Film Corp Preparation of sulfate esters by the reaction of chlorosulfonic acid with alkoxylated alkyl phenols
US4031622A (en) * 1975-10-28 1977-06-28 Wells Manufacturing Corporation Portable power driven implement
US4254095A (en) * 1978-04-27 1981-03-03 Research Corporation Radioimmunoassay for erythropoietin
JPH07116031B2 (ja) 1986-09-24 1995-12-13 株式会社アドバンス 制癌剤
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5158978A (en) 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
WO1991011181A1 (en) 1990-02-05 1991-08-08 British Technology Group (Usa) Incorporated Thyroid hormone cardiac treatment
US5272078A (en) * 1991-01-29 1993-12-21 Brigham And Women's Hospital CDNA encoding the type I iodothyronine 5'deiodinase
US6498037B1 (en) 1991-03-04 2002-12-24 Bayer Corporation Method of handling reagents in a random access protocol
US5225204A (en) 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
DK0550108T3 (da) 1991-12-30 1999-01-04 Akzo Nobel Nv Thyreoaktiv sammensætning med langvarig frigivelse
KR950010051Y1 (ko) 1993-10-15 1995-11-25 이해섭 휴대용 절첩테이블
GB9401892D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
DE19541128C2 (de) 1995-10-27 1997-11-27 Henning Berlin Gmbh & Co Stabilisierte schilddrüsenhormonhaltige Arzneimittel
AU712217B2 (en) 1995-11-14 1999-11-04 Abbott Gmbh & Co. Kg Stabilized thyroid hormone preparations and methods of making same
EP1078265A1 (de) 1998-02-18 2001-02-28 Dade Behring Inc. Chemilumineszente verbindungen zur detektion einer mehrzahl von analyten
DE19821625C1 (de) 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6599942B1 (en) * 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
EP1307741A4 (de) * 2000-07-26 2005-11-23 Biodiagnostics Inc Verfahren zur diagnose von thyroidparametern und zum überwachen von thyroxintherapien
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US6979462B1 (en) 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6855333B1 (en) 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US20030224047A1 (en) 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
ITMI20011401A1 (it) 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
DE10136615A1 (de) 2001-07-17 2003-02-06 Berlin Chemie Ag Schilddrüsentherapeutika
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030195253A1 (en) 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20022777A1 (it) 2002-12-27 2004-06-28 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
US20040156893A1 (en) 2003-02-11 2004-08-12 Irwin Klein Method for treating hypothyroidism
WO2004096177A1 (de) 2003-05-02 2004-11-11 Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze
US8293272B2 (en) 2003-05-02 2012-10-23 Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
GB0316206D0 (en) 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
SI2801354T1 (sl) 2004-10-08 2017-07-31 Forward Pharma A/S Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
AU2007267612A1 (en) 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
EP1958617B1 (de) 2007-02-14 2010-09-08 Laboratorios Lesvi, S.L. Pharmazeutische Zusammensetzungen mit Quetiapinfumarat
AU2008240374A1 (en) 2007-04-23 2008-10-30 Diurnal Limited Sustained release
EP1992341A1 (de) 2007-05-16 2008-11-19 Université Joseph Fourier Neue pharmazeutische Zusammensetzungen mit einem Schilddrüsenhormon und ihre therapeutische Verwendung
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
FR2931359B1 (fr) 2008-05-20 2012-12-21 Menvielle Bourg Fabienne Joanny Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice
KR102023255B1 (ko) 2009-04-01 2019-09-19 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
CN102259831A (zh) 2010-05-27 2011-11-30 清华大学 三维纳米结构阵列

Also Published As

Publication number Publication date
EP1767202A1 (de) 2007-03-28
CN101406467A (zh) 2009-04-15
JP2011102306A (ja) 2011-05-26
AU2003292006A1 (en) 2004-06-03
ES2273045T3 (es) 2007-05-01
WO2004043452A1 (en) 2004-05-27
US9044441B2 (en) 2015-06-02
DE60308718D1 (de) 2006-11-09
US20130146502A1 (en) 2013-06-13
US20170007563A1 (en) 2017-01-12
CY1107312T1 (el) 2012-11-21
JP2006508956A (ja) 2006-03-16
US9468619B2 (en) 2016-10-18
JP5301074B2 (ja) 2013-09-25
US20130281536A1 (en) 2013-10-24
EP1560575B1 (de) 2006-09-27
DE60308718T2 (de) 2007-08-02
US20050272816A1 (en) 2005-12-08
US9012438B2 (en) 2015-04-21
PT1560575E (pt) 2007-01-31
US10238615B2 (en) 2019-03-26
EP1560575A1 (de) 2005-08-10
CN1711079A (zh) 2005-12-21
DK1560575T3 (da) 2007-01-29
ITMI20022394A1 (it) 2004-05-14
US20110245342A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
DE60308718D1 (de) 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
GB0225474D0 (en) Therapeutic agents
BR0317696A (pt) Composição para branqueamento
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
CY1111867T1 (el) Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
ATE514418T1 (de) Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
BR0112770A (pt) Agentes herbicidas
ATE319467T1 (de) Formulierungen zur behandlung von männlicher und weiblicher impotenz
EP1781277A4 (de) Kombinationspräparat
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
BR0316796A (pt) Processos para redução da concentração de mehq em ácido acrìlico e para preparação de superabsorventes
CY1111900T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda)
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
EP1496742A4 (de) Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
BRPI0409586A (pt) ácidos hidroxámicos úteis no tratamento de distúrbios hiperproliferativos
TR199500984A2 (tr) Selegilin'in epileptik hastaliklarin tedavisinde kullanimi.
FI20030379A0 (fi) Uusi farmaseuttinen koostumus
BRPI0415428A (pt) formulações terapêuticas
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE60322871D1 (de) Thaltende zubereitungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1560575

Country of ref document: EP